Top Markets
#1 Siren Siren +38.07%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.61%
#3 RedStone RedStone +20.14%
#4 Verus Coin Verus Coin +18.07%
#5 Cysic Cysic +17.41%
#6 Ocean Protocol Ocean Protocol +16.25%
#7 Perle Perle +14.21%
#8 KUB Coin KUB Coin +13.13%
#9 OpenEden OpenEden +12.87%
#10 Arowana Arowana +12.55%
Coin of the day
Siren Siren
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Advanced Biomed Inc. Common Stock Advanced Biomed Inc. Common Stock

Advanced Biomed Inc. Common Stock

ADVB
Classificação em ações #31831
Advanced Biomed Inc. functions as an investment holding company, primarily... Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.
Preço da ação
$8.65
Última sincronização: 2026-08-17
Valor de mercado
$11.96M
Variação (1 dia)
-3.35%
Variação (1 ano)
2.98%
País
US
Negociar Advanced Biomed Inc. Common Stock (ADVB)

Categoria

Healthcare
Rácio P/E de Advanced Biomed Inc. Common Stock (ADVB)
Rácio P/E em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Advanced Biomed Inc. Common Stock, o rácio P/E atual (TTM) é 0. No final de 2026, a empresa tinha um P/E de 0.
Histórico do rácio P/E da Advanced Biomed Inc. Common Stock de 2026 a 2026
Rácio P/E no final de cada ano
Ano Índice P/E Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/E para empresas semelhantes ou concorrentes
Empresa Rácio P/E Diferença do rácio P/E País
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 31.59 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 35.83 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -227.89 -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 38.69 -
US
Como interpretar um P/E Ratio?

O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.

Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.

Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.